Valneva SE
Cerrado
2.93 1.03
Resumen
Variación precio
24h
Mínimo
2.93
Máximo
2.95
Ingresos | 870K -31M |
|---|---|
Ventas | 4M 35M |
BPA | -0.17 |
Margen de beneficios | -89.312 |
Empleados | 620 |
EBITDA | -2.3M -23M |
Próximas Ganancias | 12 nov 2026 |
|---|
Capitalización Mercado | 49M 561M |
|---|---|
Apertura anterior | 1.9 |
Cierre anterior | 2.93 |
Valneva SE Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Valneva SE previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
